Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer
JAMA · 01.04.2025 · 333 (13) · 1150
DOI: 10.1001/jama.2024.26886 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 01.04.2025. Verfasst von Michail Ignatiadis und 40 weiteren Autor:innen. Beteiligte Einrichtung: Institut Jules Bordet, l'Université Libre de Bruxelles and Hôpital Universitaire de Bruxelles, Brussels, Belgium. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Triple-negative breast cancer is an aggressive subtype with a high incidence in young patients, a high incidence in non-Hispanic Black women, and a high risk of progression to metastatic cancer, a devastating sequela with a 12- to 18-month life expectancy. Until recently, one strategy for treating early-stage triple-negative breast cancer was chemotherapy after surgery. However, it was not known whether the addition of immune therapy to postsurgery chemotherapy would be beneficial.
Objective
To evaluate the addition of immune therapy in the form of atezolizumab to postoperative chemotherapy in patients with the high-risk triple-negative breast cancer subtype. Design, Setting, and Participants In this open-label international randomized phase 3 trial conducted in more than 330 centers in 31 countries, patients undergoing surgery as initial treatment for stage II or III triple-negative breast cancer were enrolled between August 2, 2018, and November 11, 2022. The last patient follow-up was on August 18, 2023.
Interventions
Patients were randomized (1:1) to receive standard chemotherapy for 20 weeks with (n = 1101) or without (n = 1098) the immune therapy drug atezolizumab for up to 1 year. Main Outcomes and Measures The primary end point was invasive disease-free survival (time between randomization and invasive breast cancer in the same or opposite breast, recurrence elsewhere in the body, or death from any cause).
Results
The median age of enrolled patients was 53 years and most self-reported as being of Asian or White race and neither Latino nor Hispanic ethnicity. The study independent data monitoring committee halted enrollment at 2199 of 2300 planned patients. All patients stopped atezolizumab following a planned early interim and futility analysis. The trial continued to a premature final analysis. With invasive disease-free survival events in 141 patients (12.8%) treated with atezolizumab-chemotherapy and 125 (11.4%) with chemotherapy alone (median follow-up, 32 months), the final stratified invasive disease-free survival hazard ratio was 1.11 (95% CI, 0.87-1.42; P = .38). Compared with chemotherapy alone, the regimen of atezolizumab plus chemotherapy was associated with more treatment-related grade 3 or 4 adverse events (54% vs 44%) but similar incidences of fatal adverse events (0.8% vs 0.6%) and adverse events leading to chemotherapy discontinuation. Chemotherapy exposure was similar in the 2 treatment groups. Conclusions and Relevance The addition of the immune therapy drug atezolizumab to chemotherapy after surgery did not provide benefit among patients with triple-negative breast cancer who are at high risk of recurrent disease. Trial Registration ClinicalTrials.gov Identifier: NCT03498716
Autor:innen und Institutionen
- Institut Jules Bordet, l'Université Libre de Bruxelles and Hôpital Universitaire de Bruxelles, Brussels, Belgium.
- Frontier Science, Kincraig, United Kingdom.
- Simmons Cancer Center at UT Southwestern Medical Center, Dallas, Texas.
- Breast International Group, Brussels, Belgium.
- Dana-Farber Cancer Institute, Boston, Massachusetts.
- Genentech Inc, South San Francisco, California.
Zitieren
APA
Ignatiadis, M., Bailey, A., McArthur, H., El-Abed, S., de Azambuja, E., Metzger, O., Chui, S. Y., Dieterich, M., Perretti, T., Shearer-Kang, E., Molinero, L., Steger, G. G., Jassem, J., Lee, S. C., Higgins, M., Zarba, J., Schmidt, M., Gomez, H., Guerrero Zotano, A., …, & Piccart, M. (2025). Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer. JAMA, 333(13), 1150. https://doi.org/10.1001/jama.2024.26886
Vancouver
Ignatiadis M, Bailey A, McArthur H, El-Abed S, de Azambuja E, Metzger O, et al. Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer. JAMA. 2025;333(13):1150. doi:10.1001/jama.2024.26886
BibTeX
@article{Ignatiadis2025,
author = {Ignatiadis, Michail and Bailey, Andrew and McArthur, Heather and El-Abed, Sarra and de Azambuja, Evandro and Metzger, Otto and Chui, Stephen Y and Dieterich, Max and Perretti, Thomas and Shearer-Kang, Esther and Molinero, Luciana and Steger, Günther G and Jassem, Jacek and Lee, Soo Chin and Higgins, Michaela and Zarba, Jose and Schmidt, Marcus and Gomez, Henry and Guerrero Zotano, Angel and Moscetti, Luca and Chiu, Joanne and Munzone, Elisabetta and Ben-Baruch, Noa Efrat and Bajetta, Emilio and Ohno, Shinji and Im, Seock-Ah and Werutsky, Gustavo and Gal-Yam, Einav Nili and Gonzalez Farre, Xavier and Tseng, Ling-Ming and Jacot, William and Gluz, Oleg and Shao, Zhimin and Shparyk, Yaroslav and Zimina, Anastasia and Winer, Eric and Cameron, David A and Viale, Giuseppe and Saji, Shigehira and Gelber, Richard and Piccart, Martine},
title = {Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer},
journal = {JAMA},
year = {2025},
volume = {333},
number = {13},
pages = {1150},
doi = {10.1001/jama.2024.26886}
}
EUVIMED